Medivation Inc (MDVN) 63.57 $MDVN Look for Shares of

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medivation Inc (MDVN) 63.57 $MDVN

Look for Shares of Medivation to Potentially Pullback after Yesterday's 2.30% Rise
Comtex SmarTrend(R) - Fri Jul 29, 1:14PM CDT
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $62.10 to a high of $64.16. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $63.20 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 63.57 (-0.42)

Medivation Announces Second Quarter 2016 Financial Results Conference Call and Webcast on August 9, 2016
Marketwire Canada - Tue Jul 26, 6:01AM CDT
SAN FRANCISCO, CA--(Marketwired - July 26, 2016) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live conference call and audio webcast with management to discuss second quarter 2016 financial results and provide a general business update on August 9, 2016 at 4:30 p.m. Eastern Time. A press release for the second quarter 2016 will be released after markets close on August 9, 2016.
MDVN: 63.57 (-0.42)

What's in Store for these 5 Drug Stocks in Q2 Earnings?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 7:24AM CDT
Medical stocks are once again expected be among the better performers in Q2. Johnson & Johnson (JNJ) and Biogen have already set the tone with beats and raised outlooks.
MDVN: 63.57 (-0.42), BIIB: 302.98 (+13.05), JNJ: 125.40 (+0.17), ALDR: 30.84 (-1.26), SGEN: 48.86 (+0.80), NEO: 8.58 (-0.14), EXAS: 18.05 (+0.67)

Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 63.57 (-0.42), BIIB: 302.98 (+13.05), VRTX: 97.78 (+0.78), GILD: 80.77 (+1.30), UNH: 143.40 (+0.20), MRK: 58.72 (+0.06), ALXN: 133.19 (+4.59), XOM: 86.01 (-2.94), CVX: 99.42 (-3.06), REGN: 433.86 (+8.74), CELG: 114.41 (+2.22)

Blog Coverage Biotech Major Medivation Open to Takeover Talks
ACCESSWIRE - Wed Jul 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / July 6, 2016 / Active Wall St. blog coverage looks at the headline from Medivation Inc. (NASDAQ: MDVN) as the U.S. company signs confidentiality agreements with Paris-based Sanofi S.A. (NYSE: SNY), Pfizer Inc. (NYSE: PFE) and Celgene Corp. (NASDAQ: CELG) among others. Register with us now for your free membership and blog access at:
MDVN: 63.57 (-0.42), PFE: 37.24 (+0.35), ABBV: 66.96 (+0.73), SNY: 42.41 (-0.22), CELG: 114.41 (+2.22)

NIH won't cut price of taxpayer-funded prostate cancer drug
By LINDA A. JOHNSON - AP - Mon Jun 20, 5:25PM CDT
TRENTON, N.J. (AP) — The federal government has declined a petition to lower the price of a drug for advanced prostate cancer developed with taxpayer money.
MDVN: 63.57 (-0.42)

Medivation Up 46.9% Since SmarTrend Uptrend Call (MDVN)
Comtex SmarTrend(R) - Fri Jun 17, 12:47PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 46.92% as of today's recent price of $59.57.
MDVN: 63.57 (-0.42)

Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:56AM CDT
Medivation (MDVN) announced data from a phase I/II study on pidilizumab for the treatment of pediatric with diffuse intrinsic pontine glioma.
MDVN: 63.57 (-0.42), ANIP: 60.25 (-0.35), PFE: 37.24 (+0.35), BMY: 75.87 (+1.06)

MEDIVATION INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches of Fiduciary Duty
GlobeNewswire - Wed Jun 15, 7:01AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc. ("Medivation" or the "Company".
MDVN: 63.57 (-0.42)

Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders
BusinessWire - Mon Jun 13, 7:39AM CDT
--Highlights the Potential of Medivation's Blockbuster XTANDI Franchise and Innovative Late Stage Pipeline to Create Significant Additional Value
MDVN: 63.57 (-0.42)

MEDIVATION (MDVN) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach of Fiduciary Duty
BusinessWire - Mon Jun 13, 7:07AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc. (NASDAQGS:MDVN) ("Medivation" or the "Company".
MDVN: 63.57 (-0.42)

Medivation Has Returned 48.2% Since SmarTrend Recommendation (MDVN)
Comtex SmarTrend(R) - Fri Jun 10, 12:21AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 48.23% as of today's recent price of $60.10.
MDVN: 63.57 (-0.42)

Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 63.57 (-0.42), SAN: 4.11 (-0.13), SNY: 42.41 (-0.22)

Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 63.57 (-0.42), ACAD: 37.18 (+0.14), OPK: 9.97 (+0.02), CLDX: 4.66 (+0.04)

Uptrend Call Working As Medivation Stock Rises 49.5% (MDVN)
Comtex SmarTrend(R) - Thu Jun 02, 12:45PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 2 months, Medivation has returned 49.48% as of today's recent price of $60.61.
MDVN: 63.57 (-0.42)

Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer
Marketwired - Thu Jun 02, 6:00AM CDT
SAN FRANCISCO, CA and TOKYO, JAPAN--(Marketwired - June 02, 2016) - Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 63.57 (-0.42)

Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer
PR Newswire - Thu Jun 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 63.57 (-0.42)

Medivation Sets Record Date for Sanofi's Proposed Consent Solicitation
BusinessWire - Wed Jun 01, 5:45PM CDT
Medivation, Inc. (NASDAQ:MDVN) today confirmed that it has received a request from Sanofi to establish a record date to determine which of the Company's stockholders are eligible to participate in the proposed solicitation of written consents by Sanofi (the "Sanofi Consent Solicitation". In accordance with that request, the Company's Board of Directors has set the close of business on June 1, 2016 as the record date for the Sanofi Consent Solicitation.
MDVN: 63.57 (-0.42)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 67

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 33

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 44

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
KuCoin Unveils $1.1M USDT Black Friday Bonanza

Updated Category News Views 0

KuCoin's Festive Fireworks: Black Friday Bonanza Sometimes the crypto world feels like a carnival, and KuCoin's latest act is the $1.1 million USDT prize pool, rolling out as part of its 'Tis The Season holiday campaign. A move that matches the glitz of Tomorrowland Winter experiences, adding more sparkle to the crypto stage. Behind the Scenes of the KuCoin-Tomorrowland...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 25

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading

Top 5 Most Recently Viewed Articles

Cypherpunk Technologies Boosts Zcash Holdings Significantly Year-Over-Year

Updated Category News Views 108

Cypherpunk Technologies Expands Zcash Accumulation CAMBRIDGE, Mass. — Cypherpunk Technologies Inc. (Nasdaq: CYPH), a company deeply engaged in privacy technology, has recently accelerated its efforts to accumulate Zcash, significantly boosting its treasury holdings. This move reflects their strategic commitment to enhancing their corporate asset portfolio and addressing...

Continue Reading
Insights from Access LIVE: The Future of Beverage Leadership

Updated Category News Views 253

Insights from Access LIVE: The Future of Beverage Leadership Leaders from the nation's largest distributors convened to share their insights on innovation, growth, and the future of the beverage alcohol industry. The session, known as "Wholesaler Power Hour — Market Drivers: Wholesale Leaders Blazing a Path to Success," took place on the LIVE Stage at Access LIVE 2025,...

Continue Reading
Understanding Microsoft's Competitive Edge in the Software Sector

Updated Category News Views 211

Dynamic Insights into Microsoft and Its Competitors In the rapidly evolving business landscape, a thorough examination of companies is vital for investors and enthusiasts alike. This article delves into a detailed comparative analysis of Microsoft (NASDAQ: MSFT) relative to its main competitors within the software industry. By evaluating essential financial metrics,...

Continue Reading
The Transformative Financial Journey of Pan American Silver Stock

Updated Category News Views 154

The Impact of Long-Term Investment in Pan American Silver Investing in stocks is often seen as a journey, and Pan American Silver (NYSE: PAAS) stands as a shining example of how patience can yield extraordinary rewards over the years. Over the last decade, Pan American Silver has surpassed market performance, boasting an annualized return of 22.95%, which is significantly...

Continue Reading
Linc Housing Initiates Construction of 90 Affordable Units

Updated Category News Views 219

Linc Housing Begins Construction on New Affordable Homes In a promising development for families in need, Linc Housing has commenced the construction of three new affordable apartment communities. This initiative will create 90 new homes specifically designed for low-income individuals and families. The timing could not be more critical, as communities grapple with an...

Continue Reading